Celcuity (NASDAQ:CELC) Given New $125.00 Price Target at Stifel Nicolaus

Celcuity (NASDAQ:CELC) Given New $125.00 Price Target at Stifel Nicolaus

Celcuity (NASDAQ:CELC – Free Report) had its price objective increased by Stifel Nicolaus from $115.00 to $125.00 in a research report released on Thursday,Benzinga reports. The brokerage currently has a buy rating on the stock. A number of other brokerages have also recently issued reports on CELC. Needham & Company LLC reaffirmed a “buy” rating and issued a $122.00 target price on shares of Celcuity in a report on Thursday. Weiss Ratings reiss…

Celcuity Inc. (CELC) Stock Analysis: Biotech Innovator With A 9.4% Upside Potential

Celcuity Inc. (NASDAQ: CELC), a clinical-stage biotechnology company, is turning heads in the healthcare sector with its innovative approach to cancer treatment. Based in Minneapolis, Minnesota, Celcuity focuses on developing targeted therapies for solid tumors, with Gedatolisib as its lead drug candidate. Gedatolisib aims to treat patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced b…